LONDON, UK / ACCESSWIRE / December 28, 2017 / Active-Investors has a free review on Air Products and Chemicals, Inc. (NYSE: APD) following the Company’s announcement that it will begin trading ex-dividend on December 29, 2017. To capture the dividend pay-out, investors are required to purchase the stock one day prior to the ex-dividend date, that is latest by end of trading session on December 28, 2017. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on APD:

www.active-investors.com/registration-sg/?symbol=APD

If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:

www.active-investors.com/registration-sg

Dividend Declared

On November 14, 2017, Air Products and Chemicals’ Board of Directors declared a quarterly dividend of $0.95 per share of common stock. The dividend is payable on February 12, 2018, to shareholders of record at the close of business on January 02, 2018.

Air Products’ indicated dividend represents a yield of 2.33%, which is higher compared to the average dividend yield of 2.25% for the Basic Materials sector. The Company has raised dividend for thirty-four consecutive years.

Dividend Insights

Air Products has a dividend payout ratio of 54.3%, which denotes that the Company spends approximately $0.54 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts’ estimates, Air Products is forecasted to report earnings of $7.65 per share for the next year, which is more than double compared to the Company’s annualized dividend of $3.80 per share.

As of September 30, 2017, Air Products and Chemicals’ cash and cash items totaled $3.27 billion compared to $1.29 billion as on December 31, 2016. For the twelve months ended September 30, 2017, the Company’s net cash provided used in operating activities totaled $2.53 billion compared to net cash provided by operating activities of $2.26 billion for the year ago same period. The Company’s strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Recent Development for Air Products

On December 18, 2017 Air Products announced that it has signed an agreement with a subsidiary of Shanxi Jincheng Anthracite Coal Mining Group, China’s leading coal mining conglomerate, for the supply of industrial gases to Phase One of Shanxi Jinmei Huayu Coal Chemical Co Ltd.’s (Jinmei Huayu’s) coal-to-clean-fuels project in Jincheng City, Shanxi Province.

Air Products and Chemicals has earlier signed a sale of equipment agreement with Jinmei Huayu to supply two air separation units (ASUs) – with a total capacity of over 4,000 tons per day – for this project, which uses coal to produce clean fuels.

Now, Air Products and Chemicals intends to buy back the two ASUs for approximately $100 million and supply industrial gases via pipelines to Jinmei Huayu under a long-term supply agreement, subject to finalization of a buy-back agreement and any government and regulatory approvals. The ASUs are expected to be onstream in mid-2018.

About Air Products and Chemicals, Inc.

Air Products and Chemicals is a world-leading Industrial Gases company in operation for over 75 years. The Company’s core industrial gases business provides atmospheric and process gases and related equipment to manufacturing markets, including refining and petrochemical, metals, electronics, and food and beverage. Air Products and Chemicals is also the world’s leading supplier of liquefied natural gas process technology and equipment.

The Company had fiscal 2017 sales of $8.2 billion from continuing operations in 50 countries and has a current market capitalization of about $35 billion.

Stock Performance Snapshot

December 27, 2017 – At Wednesday’s closing bell, Air Products and Chemicals’ stock slightly climbed 0.41%, ending the trading session at $163.67.

Volume traded for the day: 936.36 thousand shares, which was above the 3-month average volume of 912.10 thousand shares.

Stock performance in the last month – up 1.70%; previous three-month period – up 8.16%; past twelve-month period – up 11.05%; and year-to-date – up 13.80%

After yesterday’s close, Air Products and Chemicals’ market cap was at $35.76 billion.

Price to Earnings (P/E) ratio was at 31.71.

The stock has a dividend yield of 2.32%.

The stock is part of the Basic Materials sector, categorized under the Chemicals – Major Diversified industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 485040

LONDON, UK / ACCESSWIRE / December 28, 2017 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company’s latest news hit the wire. On December 26, 2017, the Company declared that the Ministry of Health, Labor, and Welfare (MHLW) in Japan has approved Soliris® (eculizumab) as a treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX). Soliris is the first and only complement inhibitor approved in Japan as a treatment for these patients.Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alexion Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ALXN

The Company submitted an application to Japan’s MHLW to extend the indication for Soliris® as a potential treatment for patients with refractory gMG in March 2017.

Approval is Based on Comprehensive Clinical Data from Phase-3 REGAIN Study

MHLW approval in Japan is based on the new indication of Soliris® on comprehensive clinical data from the Phase-3, randomized, double-blind, placebo-controlled, multicenter REGAIN study (ECU-MG-301). In the Phase-3 REGAIN study and its ongoing open-label extension study, Soliris® demonstrated treatment benefits for patients with anti-AChR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms, which can include difficulties seeing, walking, talking, swallowing and breathing. These patients are at an increased risk of disease exacerbations and crises that may require hospitalization and intensive care and may be life-threatening.

FDA and EU Approved Soliris For Treatment of Patients With gMG

On October 23, 2017, the US Food and Drug Administration (FDA) approved Soliris® as a treatment for adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. In August 2017, European Commission (EU) also approved Soliris® for the treatment of refractory gMG in adults who are anti-acetylcholine receptor antibody-positive. Soliris is the first® and only complement-based therapy approved in the EU for this ultra-rare subset of patients.

About Soliris® (eculizumab)

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris® works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a role in serious diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis.

About Generalized Myasthenia Gravis (gMG)

Myasthenia gravis (MG) is a debilitating, chronic, long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma. The disease can occur at any age but most commonly begins for women before the age of 40 and men after the age of 60.

About Alexion Pharmaceuticals, Inc.

Founded in 1992, Alexion Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company’s three highly innovative therapies treat patients with four severe and ultra-rare diseases. Alexion Pharma is headquartered in New Haven, Connecticut.

Stock Performance Snapshot

December 27, 2017 – At Wednesday’s closing bell, Alexion Pharma’s stock marginally climbed 0.49%, ending the trading session at $119.80.

Volume traded for the day: 1.30 million shares.

Stock performance in the last month – up 11.18%

After yesterday’s close, Alexion Pharma’s market cap was at $26.64 billion.

Price to Earnings (P/E) ratio was at 53.55.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 485041

Stock Monitor: American Eagle Outfitters Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 28, 2017 / Active-Investors.com has just released a free earnings report on Ross Stores, Inc. (NASDAQ: ROST). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ROST. The Company posted its financial results on November 16, 2017, for the third quarter of the fiscal year 2017. The department stores’ revenue and adjusted EPS surpassed analysts’ expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for American Eagle Outfitters, Inc. (NYSE: AEO), which also belongs to the Services sector as the Company Ross Stores. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AEO

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Ross Stores most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ROST

Earnings Highlights and Summary

For the three months ended October 28, 2017, Ross Stores’ revenue increased 8% to $3.33 billion from $3.09 billion in Q3 FY16, while its comparable store sales growth was 4%. The Company’s revenue numbers surpassed analysts’ expectations of $3.26 billion.

During Q3 FY17, the Company had 1,627 stores compared to 1,535 stores in the same period of last year.

During Q3 FY17, Ross Stores’ gross profit increased 9% to $959.75 million from $880.60 million in the comparable period of last year. For the reported quarter, the Company’s gross margin increased 30 basis points to 28.8% of revenue from 28.5% of revenue in Q3 FY16.

During Q3 FY17, Ross Stores’ operating income increased 13.3% to $442.45 million from $390.42 million in the corresponding period of last year. For the reported quarter, the Company’s operating margin increased 70 basis points to 13.3% of revenue from 12.6% of revenue in Q3 FY16, due to a combination of higher merchandise margin and leverage on above-plan sales.

During Q3 FY17, Ross Stores’ earnings before tax (EBT) increased 14.1% to $440.67 million from $386.27 million in the same period of last year. For the reported quarter, the Company’s EBT margin increased 70 basis points to 13.2% of revenue from 12.5% of revenue in Q3 FY16.

For the reported quarter, Ross Stores’ net income increased 12.2% to $274.45 million on a y-o-y basis from $244.55 million in Q3 FY16. During Q3 FY17, the Company’s diluted earnings per share (EPS) increased 16% to $0.72 on a y-o-y basis from $0.62 in the comparable period of last year, surpassing analysts’ expectations of $0.67.

Balance Sheet

As on October 28, 2017, Ross Stores’ cash and cash equivalents increased 30.2% to $1.14 billion from $878.81 million as on October 29, 2016. For the reported quarter, the Company’s long-term debt increased 0.1% to $396.85 million from $396.38 million in Q3 FY16.

For the reported quarter, the Company’s accounts receivables increased 12.8% to $103.07 million from $91.36 million in Q3 FY16. For the reported quarter, the Company’s accounts payable increased 12.2% to $1.29 billion from $1.15 billion in Q3 FY16.

In the first nine months of 2017, the Company’s net cash provided by operating activities increased 13.3% to $1.17 billion from $1.03 billion in the corresponding period of last year.

During Q3 FY17, the Company repurchased 3.6 million shares for a total of $219 million.

On November 15, 2017, the Company’s Board of Directors declared a quarterly cash dividend of $.16 per common share, payable on December 29, 2017, to stockholders of record as of December 01, 2017.

Outlook

For Q4 FY17, Ross Stores expects comparable store sales growth to be in the range of 2% – 3%, and estimates diluted EPS to be in the band of $0.88 – $0.92.

For FY17, the Company estimates diluted EPS to be in the range of $3.24 – $3.28.

Stock Performance Snapshot

December 27, 2017 – At Wednesday’s closing bell, Ross Stores’ stock marginally dropped 0.28%, ending the trading session at $80.73.

Volume traded for the day: 958.00 thousand shares.

Stock performance in the last month – up 13.18%; previous three-month period – up 24.51%; past twelve-month period – up 20.22%; and year-to-date – up 23.06%

After yesterday’s close, Ross Stores’ market cap was at $30.74 billion.

Price to Earnings (P/E) ratio was at 25.79.

The stock has a dividend yield of 0.79%.

The stock is part of the Services sector, categorized under the Apparel Stores industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 485042

VANCOUVER, BC / ACCESSWIRE / December 28, 2017 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. (TSX-V: AMY; OTC PINK: AMYZF; FRA: 2AM) (“AMI” or the “Company”), is pleased to announce that Longford Resources (“Longford”), having successfully completed due diligence on the high-grade Hazelton Cobalt-Copper-Gold Project at New Hazelton, British Columbia, Canada, will exercise its right to earn an initial 60% interest in the Project from AMI.

Highlights

Longford satisfactorily completed due diligence on the high-grade Hazelton Cobalt-Copper-Gold Project in British Columbia, Canada
The Hazelton Project includes 3 historic mines:
– Victoria Mine – Where metal grades averaged 123.4 g/t gold and 2.8% cobalt
– Rocher Deboule Mine – Where metal grades averaged 5.9% copper and 2.9 g/t gold
– Highland Boy Mine – Where metal grades averaged 7.0% copper and 1.8 g/t gold

Longford believes there is considerable exploration upside at the Project and, having completed the due diligence to its satisfaction, it has:

1. Paid AMI (CDN)$10,000; and
2. Issued AMI 50,000 shares in Longford to maintain its right to earn an initial 60% interest in the Project. To achieve this Longford is required to: Expend (CDN)$2,000,000 on the Project over 4 years; with annual option payments of (CDN)$10,000 and 50,000 shares due to AMI annually over the next 4 years.

According to AMI CEO Larry W. Reaugh, “Commencing next summer, Longford will be advancing the Hazelton high grade prospects, especially for cobalt/copper/gold in the field with a solid four-year plan. The Longford agreement allows AMI to realize value from its Hazelton holdings, while allowing the Company to maintain its core focus on our promising battery materials recycling work, and extend our patented process to the recovery of additional rare metals and minerals.”

About American Manganese Inc.

American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries. Interest in the Company’s patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become an industry leader in the recycling of spent electric vehicle lithium ion batteries having cathode chemistries such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, and Lithium-Manganese (Please see the Company’s July 27, 2017 press release for further details).

The company has updated their PowerPoint which can be viewed here.

On behalf of Management
AMERICAN MANGANESE INC.

Larry W. Reaugh
President and Chief Executive Officer

Information Contact:

Larry W. Reaugh
President and Chief Executive Officer
Telephone: 778-574-4444; Email: lreaugh@amymn.com
www.americanmanganeseinc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements,” which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

SOURCE: American Manganese Inc.

ReleaseID: 485009